Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


For the Patient
Educational Resources
Clinical Trial Information
Professional Services



 

HIV

Note: The Company's clinical trials are not necessarily indicative of future clinical trials or approvals.
 
LDO 101
A Randomized, Dose-Ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects

AMP 720
The Role of Ampligen® in Strategic Therapeutic Intervention (STI) of HAART: A Multi-Center, Randomized, Controlled Study of Ampligen® Potentiation of the HAART-Free Interval.

 
 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.